Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 133

Sort by

Sort Order Select

Journal Articles

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Bernice Oh, MBBS, MRCP, Shawn Lee, MD, Zelia Seeto, Germaine Liew, Bsc, Edwynn Chiew, MBBS, Zhi Wei Chen, Bsc, Yiong Huak Chan, PhD, Jing Jia Eng, Bsc, Koon Mian Foo, Bsc, Ching Mei Joyce Lam, MD, Ah Moy Tan, MD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1307.

https://doi.org/10.1182/blood-2019-122098

Published: 2019

Journal Articles

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Seth M Maliske, MD, Matthew J. Maurer, MS, Carrie A. Thompson, MD, Luis Porrata, MD, Ivana Micallef, MD, Rebecca L. King, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Margarida Magalhaes Silverman, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, David James J Inwards, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Patrick Johnston, MD PhD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 2896.

https://doi.org/10.1182/blood-2019-124579

Published: 2019

Journal Articles

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

Theodora Anagnostou, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Shahrzad Jalali, PhD, Jose C Villasboas, Hongyan Wu, PhD, Tammy Price-Troska, BS, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2790.

https://doi.org/10.1182/blood-2019-127757

Published: 2019

Journal Articles

RNA Sequencing in Childhood B-Lymphoblastic Leukemia Improves Molecular and Risk Assignment

Allen Eng Juh Yeoh, MD, Zhenhua Li, PhD, Shawn Lee, MD, Winnie Hui Ni Chin, Nan Jiang, PhD, Yi Lu, PhD, Shirley Kow Yin Kham, BSc, Ah Moy Tan, MD, Hai_peng Lin, Thuan Chong Quah, Hany Ariffin, Jun J. Yang, PhD

Blood (2019) 134 (Supplement_1): 651.

https://doi.org/10.1182/blood-2019-131653

Published: 2019

Journal Articles

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Melissa C Larson, MS, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas M. Habermann, MD, Sunnia T Chen, BS, Hector R Villarraga, MD, Joerg Herrmann, MD, Gita Thanarajasingam, MD, Alessia Castellino, MD, Grzegorz Nowakowski, MD, David J Inwards, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 422.

https://doi.org/10.1182/blood-2019-127203

Published: 2019

Journal Articles

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Blood (2019) 134 (Supplement_1): 400.

https://doi.org/10.1182/blood-2019-124017

Published: 2019

Journal Articles

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Sunnia T Chen, BS, Nicholas J Boddicker, PhD, Matthew J. Maurer, MS, Cristine Allmer, BS, Dennis P. Robinson, Grzegorz Nowakowski, MD, Thomas M. Habermann, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, James R. Cerhan, MD PhD

Blood (2019) 134 (Supplement_1): 5215.

https://doi.org/10.1182/blood-2019-128775

Published: 2019

Journal Articles

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

Keenan T. Hartert, PhD, Kerstin Wenzl, PhD, Jordan Krull, Michelle Manske, MS, BS, Vivekananda Sarangi, Melissa C Larson, Theodora Anagnostou, MD, Ellen D. McPhail, MD, Brian K. Link, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Dragan Jevremovic, MD PhD, Anne J Novak, PhD

Blood (2019) 134 (Supplement_1): 2764.

https://doi.org/10.1182/blood-2019-128803

Published: 2019

Journal Articles

RNA-Seq Can Help Identify IGH Disease Clones for MRD Monitoring in Childhood B-Lymphoblastic Leukemia

Zhenhua Li, PhD, Nan Jiang, PhD, Evelyn Huizi Lim, Winnie Hui Ni Chin, Shirley Kow Yin Kham, BSc, Wentao Yang, Thuan Chong Quah, Hai_peng Lin, Ah Moy Tan, MD, Hany Ariffin, Jun J. Yang, PhD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1471.

https://doi.org/10.1182/blood-2019-131548

Published: 2019

Journal Articles

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Namrata Singh, MD, Sarah L Mott, Ashley Noel McCarthy, MPH, Sergei Syrbu, MD PhD, Thomas M. Habermann, MD, Andrew L. Feldman, MD, Susan L Slager, PhD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Umar Farooq, MD, James R. Cerhan, MD PhD, Zuhair Ballas, Brian K. Link, MD

Blood (2019) 134 (Supplement_1): 1604.

https://doi.org/10.1182/blood-2019-122737

Published: 2019

Journal Articles

Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways

Blood (2019) 134 (Supplement_1): 1480.

https://doi.org/10.1182/blood-2019-126860

Published: 2019

Journal Articles

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2019) 134 (Supplement_1): 919.

https://doi.org/10.1182/blood-2019-123694

Published: 2019

Journal Articles

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Blood (2019) 134 (Supplement_1): 923.

https://doi.org/10.1182/blood-2019-122756

Published: 2019

Journal Articles

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Matthew J Maurer, MS, Amy S. Ruppert, MAS, PhD, Brian K. Link, MD, Lawrence D Kaplan, MD, David J Inwards, MD, Andrew L. Feldman, MD, Eric D. Hsi, MD, Adam Pettinger, Jonathon B. Cohen, MD MS, Peter Martin, FRCPC, MD MS, Brad S Kahl, MD, Nancy L. Bartlett, MD, James R. Cerhan, MD PhD, John P. Leonard, MD, Thomas M. Habermann, MD

Blood (2018) 132 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2018-99-110558

Published: 2018

Journal Articles

Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma

Patrick M. Reagan, MD, Andrea M Baran, MS, Matthew J. Maurer, MS, Andrew L. Feldman, MD, Thomas M. Habermann, MD, Susan L. Slager, PhD, Gita Thanarajasingam, MD, Kathleen J Yost, PhD, Brian K. Link, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2018) 132 (Supplement 1): 3579.

https://doi.org/10.1182/blood-2018-99-118356

Published: 2018

Journal Articles

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Hidong Kim, MD, Laura Harper, MD, Thomas M. Habermann, MD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Patrick Johnston, Thomas E. Witzig, MD, Cristine Allmer, BS, Matthew J. Maurer, MS, James R. Cerhan, MD PhD, Jason Young, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2018-99-117711

Published: 2018

Journal Articles

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Matthew J. Maurer, MS, Umar Farooq, MD, Madison M Wahlen, Thomas M. Habermann, MD, Gita Thanarajasingam, MD, Sergei Syrbu, MD PhD, William R. Macon, MD, Patrick Johnston, MD, Ivana Micallef, MD, Luis Porrata, MD, Susan L. Slager, PhD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Brian K. Link, MD

Blood (2018) 132 (Supplement 1): 4204.

https://doi.org/10.1182/blood-2018-99-114331

Published: 2018

Journal Articles

Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)

Thomas M. Habermann, MD, Angelo Fama, MD, Kay M. Ristow, BS, Matthew J. Maurer, MS, William R. Macon, MD, Stephen M. Ansell, MD PhD, Nabila Nora Bennani, MD, Yogish C Kudva, MBBS, Randall C. Walker, MD, Kimberly D. Watt, Thomas R. Schwab, MD, James R. Cerhan, MD PhD, Rebecca L King, MD

Blood (2018) 132 (Supplement 1): 456.

https://doi.org/10.1182/blood-2018-99-113667

Published: 2018

Journal Articles

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

Alessia Castellino, MD, Melissa C. Larson, MS, Matthew J. Maurer, MS, Susan L. Slager, PhD, Cristine Allmer, BS, Jonathon B. Cohen, MD MS, Andrew L. Feldman, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Umar Farooq, MD, David J Inwards, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 4140.

https://doi.org/10.1182/blood-2018-99-119595

Published: 2018

Journal Articles

Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Yucai Wang, MD, Umar Farooq, MD, Brian K. Link, MD, Mehrdad Hefazi, MD, Cristine Allmer, BS, Matthew J. Maurer, MS, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD PhD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 454.

https://doi.org/10.1182/blood-2018-99-113213

Published: 2018

NARROW

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

RNA Sequencing in Childhood B-Lymphoblastic Leukemia Improves Molecular and Risk Assignment

Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)

Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

RNA-Seq Can Help Identify IGH Disease Clones for MRD Monitoring in Childhood B-Lymphoblastic Leukemia

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only